Diagnosing Chromosomal Translocations In Solid Tumours
Funder
National Health and Medical Research Council
Funding Amount
$410,997.00
Summary
Mis-repair of broken chromosomes can fuse together genes that then cause cancer. Current clinical tests are only capable of detecting single well-known gene fusions and are incapable of identifying new fusion events or fusion variations. We have developed a diagnostic technology, termed CaptureSeq, that is capable of finding all fusion genes in a patient sample. In this grant, we will demonstrate the use and advantages of CaptureSeq for diagnosing fusion genes in cancer patients.
Development Of Novel Gene Therapy Vectors For Thalassaemia
Funder
National Health and Medical Research Council
Funding Amount
$287,307.00
Summary
Thalassaemia, is a common inherited disorder affecting haemoglobin synthesis. Synthesis of ?/?-globin chain is balanced during normal red blood cell production. Any disruption in the ratio of ?/?-globin chain results in anaemia. In this study, we will explore gene therapy strategies to restore balanced ?:? globin expression and ultimately improve the severely anaemic phenotype in ?-thalassaemia patients.
Development Of A Blood-based Screening Test For Colorectal Neoplasia; Biomarker Expression In Circulating Tumor Cells And Tumor-derived Microvesicles
Funder
National Health and Medical Research Council
Funding Amount
$513,938.00
Summary
A blood-based test for bowel cancer and the premalignant lesion (i.e. adenomas) has potential to improve several aspects of screening for bowel cancer – improved capacity to detect lesions in well people who do not suspect their presence, avoidance of faecal sampling and fewer false-positive results. There is no reliable simple screening test for adenomas. This study aims at developing a practical blood test based on a device that filters and enriches cells from blood that carry these markers
Optimisation Of A Potent And Fast Acting Antimalarial Class That Is Orally Efficacious In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$683,916.00
Summary
Malaria is a devastating disease that results in 600 000 deaths annually. Current therapeutics used to combat malaria have a limited duration of use in the clinic due to the onset of resistance. We have identified a highly active antimalarial series that we propose to further develop to meet the prerequisites required for partnership with the Medicines for Malaria Venture (MMV) for progression into the clinic.
Dengue virus is the most important mosquito-borne viral disease, with 2/3 of the world's population at risk. There is currently no treatment available for dengue. Our proposal aims to progress a safe and effective new treatment (4-HPR) against Dengue towards the clinic, generating all the required pharmacokinetic and pre-clinical animal data necessary to progress to a future clinical trial in humans. We will also investigate the use of 4-HPR as a dengue preventative.
A Novel Strategy To Enhance T Cell-mediated Immunity To Vaccine Antigens
Funder
National Health and Medical Research Council
Funding Amount
$234,592.00
Summary
Globally there are about 33 million people living with HIV. The disease has already resulted in 23 million deaths and 2.5 million people are newly infected each year. Similarly, TB kills nearly 2 million people every year and infects about 1% of the worldÍs population every year. A vaccine is the best and also likely the only long-term solution for HIV/TB disease prevention. This research proposal looks at novel strategies to increase the efficacy of vaccines for diseases such as HIV/TB.